William Blair & Company
ADMS

William Blair & Company’s Adamas Pharmaceuticals ADMS Stock Holding History

William Blair & Company’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-7,500
Closed -$159K – 1454
2017
Q3 		$159K Buy
+7,500
New +$137K ﹤0.01% 1275

Other funds holding ADMS

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

William Blair & Company's ADMS Position: Q3 2018 in Review

William Blair & Company sold out of Adamas Pharmaceuticals (ADMS) in Q3 2018, closing a stake of 12,020 shares — an estimated $310K sold.

William Blair & Company first reported a position in ADMS in Q1 2016 and held it in 5 quarters. The position peaked at $434K in Q4 2017. 125 funds tracked by Wall St. Rank hold ADMS as of Q3 2018.

  • William Blair & Company reported no remaining Adamas Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • William Blair & Company sold 12,020 Adamas Pharmaceuticals shares in Q3 2018, an estimated $310K.
  • William Blair & Company first reported a position in Adamas Pharmaceuticals in Q1 2016 and held it in 5 quarters.
  • William Blair & Company's Adamas Pharmaceuticals position peaked at $434K in Q4 2017.
  • 125 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2018.

Based on William Blair & Company's 13F filing for Q3 2018, filed 13 Nov 2018.